key: cord-0329014-66w1bps2
authors: Zhou, Shouhao; Liu, Xinyi; Fang, Xinying; Chinchilli, Vernon M.; Wang, Michael; Wang, Hong-Gang; Dokholyan, Nikolay V; Shen, Chan; Lee, J Jack
title: Robust and Efficient Assessment of Potency (REAP): A Quantitative Tool for Dose-response Curve Estimation
date: 2021-11-22
journal: bioRxiv
DOI: 10.1101/2021.11.20.469388
sha: c471f28af83aa08440fa930e97a996aefbf33823
doc_id: 329014
cord_uid: 66w1bps2

The median-effect equation has been widely used to describe the dose-response relationship and identify agents that activate or inhibit specific disease targets in contemporary drug discovery. However, the experimental data often contain extreme responses, which may significantly impair the estimation accuracy and impede valid quantitative assessment in the standard estimation procedure. To improve the quantitative estimation of the dose-response relationship, we introduce a novel approach based on robust beta regression. Substantive simulation studies under various scenarios demonstrate solid evidence that the proposed approach consistently provides robust estimation for the median-effect equation, particularly when there are extreme outcome observations. Moreover, simulation studies illustrate that the proposed approach also provides a narrower confidence interval, suggesting a higher power in statistical testing. Finally, to efficiently and conveniently perform common lab data analyses, we develop a freely accessible web-based analytic tool to facilitate the quantitative implementation of the proposed approach for the scientific community.

The median-effect equation is a unified theory in medicine to describe the dose-response relationship and identify agents or their combinations that activate or inhibit specific disease targets 1 . It is a fundamental method established based on the pharmacological principle of mass-action law 2 . As the common link for many biomedical systems, it has been used extensively to analyze in vitro experimental data and evaluate the potency of related drugs [3] [4] [5] [6] .

In practice, the median-effect equation can be estimated for drug efficacy or pathway inhibition from normalized data generated from experimental studies. Without knowing the true dose-effect curve during the experimental design and data collection, it is common to observe extreme values of (un)affected cell fraction that is close to the response of either 0 or 100% in the analytic dataset. Quantitatively, it poses a special analytic challenge to estimate the median-effect question in practice. The standard estimation approach, often based on a linear regression model after a logit transformation 7, 8 , could suffer badly from poor estimation in such situations. Fig. 1 illustrates a preliminary example in that the standard approach is deficient in describing the median effect curve with a perturbation in one extreme data point. The variation in real experimental data, mostly caused by unavoidable measurement error, often at a much larger degree, therefore challenges the reliability of result presentation and interpretation for many drug assessment studies.

Additionally, the modeling strategy by deleting extreme values may not be feasible in many situations 9 .

For example, a meaningful drug concentration could consist of high inhibition (>90%) or low cell viability (<10%) in cancer research. It is not logical to ignore extreme observations when they are indeed biologically relevant for the target effect, not even to mention an associated loss of power by leaving fewer data points for estimation.

Furthermore, it is dubious to apply the constant error variance, a default assumption in standard linear regression modeling, in dose-response estimation. As an assumption can be examined with repeated measures, many dose-response data have indicated either a constant variance before logit transformation or a positive correlation with drug dose. It is incongruous to apply linear regression if the assumption is violated due to error heteroscedasticity 10, 11 . Therefore, it is essential to develop a robust quantitative approach to estimating the median-effect equation.

Here, we introduce a novel approach to improving the quantitative assessment of dose-response relationship and drug potency, together with a user-friendly web-based analytic tool to facilitate the implementation. The proposed method to estimate the median-effect equation is established in the robust beta regression framework, which not only takes the beta law to account for non-normality and heteroskedasticity 12 , but also minimizes the average density power divergence (DPD) using a tuning parameter, which compensates for the lack of robustness against outliers under the standard beta regression 13 . Results from simulation studies under various scenarios confirm that the proposed approach consistently gives robust estimation for the median-effect equation. Particularly, we examine two important measures for drug binding affinity: the Hill coefficient, which signifies the sigmoidicity of the curve, and overall effect, indicated by dose concentration for a specified (e.g., 50%) response 14, 15 . When there are extreme outcome observations, the improvement of robust beta regression in estimation accuracy could be substantial. Moreover, simulation studies further illustrate that the proposed approach provides a narrower confidence interval, which in turn suggests a higher efficiency to achieve better power in statistical testing even without acquiring additional experimental data. Illustrative examples using real-world data for cancer research and SARS-CoV-2 treatment are provided. The analyses are implemented using the freely accessible web-based application REAP, developed based on the Shiny package of R language, with which research scientists could conveniently upload their drug experiment dataset and perform the data analysis.

The median-effect equation describes a popular model of the dose-response relationship based on the median effect principle of the mass action law in various biological systems 2 . Assume and are the fractions of the system affected and unaffected by a drug concentration . The median-effect equation

where is the Hill coefficient signifying the sigmoidicity of the dose-effect curve and is the dose of a drug required to produce the median effect, which is analogous to the more familiar 50 (drug concentration that causes 50% of the maximum inhibitory effect), 50 (half-maximum effective dose), or 50 (median lethal dose) values 13 . For example, if an inhibitory substance is of interest, the parameter measures the cooperativity in the binding of multiple ligands to linked binding sites, and the parameter = 50 , defined by the concentration that causes 50% of the maximum inhibitory effect.

Given + = 1, the median-effect equation (1) is equivalent to

where logit( ) denotes the logit function log 1− . The equation (2) shows a log-linear relationship between the drug dose and its effect (or , if it is, for example, the % survival of interest) after a logit transformation. Because from a modeling perspective the identical strategy can be applied to model both and , for the effect on cell fraction , we can re-write equation (2) to be:

where 0 is the intercept and 1 the slope of the response curve. In this presentation, the median effect

the Hill coefficient

and the dose-response curve

where

is the inverse-logit function.

The effect and the parameters = ( 0 , 1 ) in equation (3) cannot be directly observed, but they can be estimated using experimental data, in which the observed sample cell fraction produced by the drug dose is a random variable with mean . It is clear that effective estimation must properly account for random variation and be based upon a model that not only matches the nature of the response variable, but adequately characterizes the observed dose-response pattern 16 .

Among all the unknown quantities, the parameters could be first estimated and play a fundamental role in supporting the inference for others. In the standard estimation procedure based on linear regression, logit( ) = log 1− is regressed on log to get the inference on parameters . Subsequently, the doseresponse curve can be estimated by equation (6) , and ( , ) can be derived based on equations (4) and 17, 18 . In a classic beta regression framework, the beta regression model uses a parameterization of the beta law that is indexed by the mean parameter , and the precision parameter that controls the overall variation 12 . To model the dose-response relationship for the cell fraction , we assume that the response is a beta-distributed random variable and its mean = has the form of equation (6), where is the dose producing effect , 1 and 0 are the regression parameters. Estimation of regression parameters can be performed using maximum likelihood method to derive point estimate ̂ and covariance matrix .

Beta regression is robust to extreme values and provides reliable estimations (Fig. 1) . Compared with the standard approach, which applies a non-linear transformation in the response for an approximation to the normal distribution, the beta density can take on a variety of shapes to account for non-normality and skewness 19 . In the presence of heteroskedasticity and asymmetry, two common problems frequently observed in limited range continuous response data, an empirical study showed that the beta regression provided the best estimation among several alternatives 20 .

The standard beta regression potentially could be sensitive against outliers because its inference is based on the maximum likelihood estimation. Ghosh 13 developed the robust minimum density power divergence estimators (MDPDE) that address the problem by minimizing the average density power divergence (DPD)

between the empirical density ̂and the beta model density function ≡ ( , (1 − ) ). is a non-negative tuning parameter, smoothly connecting the likelihood disparity (at = 0) to the L2-Divergence (at = 1). The parameter of interest is estimated by minimizing the DPD measure between and the density, ̂, estimated by data:

or equivalently, minimizing the objective function using the estimation equations:

. MDPDE improves the standard beta regression with the DPD measure and a fixed tuning parameter. The recommended is around 0.3 to 0.4, but simply assigning a fixed in [0.3,0.4] is not applicable in many cases. Here we adopted a data-driven method 21 to identify the optimal . The search for the optimal starts with a grid of and a pre-defined and grid size , which generates a sequence of equally

. MDPDE calculates the corresponding and ( ) with each so that we get a vector of standardized estimates:

) .

The standardized quadratic variations (SQV) are defined by:

We compare each with a pre-defined threshold ( > 0). If all satisfy the stability condition of < , then the optimal equals the minimal in . Otherwise, restart the search with a new grid of . The new grid of the same size is picked from the sequence { } =0 starting from the largest that fails the stability condition. Repeat searching until the current grid satisfies the stability condition or is reached. If the stability condition is satisfied before is reached, then optimal equals the minimal value in the grid of . If is reached, then optimal equals 0, which is equivalent to the maximum likelihood estimation.

The objective of analysis is to characterize the dose-response curves in equation (2) and quantify in vitro drug potency. Popular drug activity measurements include Hill coefficient and median effect dose .

In some circumstances, other measurements such as instantaneous inhibitory potential (IIP), which directly quantifies the log decrease in single-round infection events caused by a drug at a clinically relevant concentration, are of special interest 22 .

The MDPDE for beta regression model provides a robust strategy to estimate , from which the point estimates and confidence intervals of relevant drug activity measurements can be derived.

Mathematically, those drug activity quantities can be written as functions of parameters with an explicit

form. Subsequently, their point estimates and confidence intervals can be derived based on the inference of . For example, given a point estimate ̂= (̂0,̂1), the point estimate for ̂, ̂ as a single value, and ̂ as a function of dose can be computed using equations (4 -6) .

It is important to construct the confidence interval around the point estimate to gauge the estimation uncertainty. With different levels of measurement error from either well-managed or lousy experiments, the levels of evidence vary for statistical inference, even if it is derived the same point estimates for the intercept 0 , slope 1 and the corresponding dose-response curve. Given the point estimate ̂ and its positive-definite covariance matrix to account for variability in observed response, we apply the multivariate delta method and approximate the variance estimate after assuming asymptotic normality 23 .

As demonstrated in our simulation studies, the constructed (1 − ) × 100% confidence interval consistently provides better results to quantify the (1 − ) × 100% coverage probability. More importantly, the width of the constructed confidence interval was narrower than that from a linear regression model, suggesting that our approach is more efficient with a higher statistical power ( Supplementary Tables 1-2) . 

We developed a user-friendly analytic tool, coined "REAP" (Robust and Efficient Assessment of Potency), for convenient application of the robust dose-response estimation to real-world data analysis. It is established in an agile modeling framework under the parameterization of the beta law to describe a continuous response variable with values in a standard unit interval (0,1). We further exploited a robust estimation method of the beta regression, named the minimum density power divergence estimators (MDPDE) 13 , for dose-response estimation, with the tuning parameter optimized by a data-driven method 21 . The technical details are provided in the Methods.

REAP presents a straightforward analytic environment for robust estimation of dose-response curve and assessment of key statistics, including implementation of statistical comparisons and delivery of customized output for graphic presentation (Fig. 2) . The dose-response curve is a time-honored tool to convey the pharmacological activity of a compound. Through dose-response curves, we can compare the relative activity of a compound on different assays or the sensitivity of different compounds on an assay.

REAP aims to make this job simple, estimation efficient, and results robust. Table 1 ). Meanwhile, the 95% CIs are much narrower (Fig. 1) In parallel, similar results are obtained consistently with data simulated using beta error term, which induces heteroscedasticity (smaller on the two ends and bigger in the middle) at different dose levels (Fig.   4, Supplementary Table 2 ). All the results above demonstrate the sensitivity of standard regression model in dealing with datasets including extreme values. In addition, the result comparisons between the sevendose set and the six-dose set with the largest or smallest dose eliminated display the potential worse influence of deleting extreme values directly in modeling dose-response using linear regression, which further notarizes the robustness and efficiency of the proposed robust beta regression.

Overall, the simulation study suggests that the robust beta regression model produces well-calibrated dose-response curves while being more robust and powerful than the standard regression model in estimating the median effect equation.

The first example of REAP application is dose-response curve estimation of the same agent under different cell lines. The data was originally from a study on using a drug called auranofin in treating B-cell lymphomas such as relapsed or refractory mantle cell lymphoma (MCL) 24 . As an FDA-approved for treatment of rheumatoid arthritis, auranofin targets thioredoxin reductase-1 (Txnrd1), and was repurposed as a potential anti-tumor drug to effectively induce DNA damage, reactive oxygen species (ROS) production, cell growth inhibition, and apoptosis in aggressive B-cell lymphomas, especially in TP53mutated or PTEN-deleted lymphomas.

In the experiment, the effect of auranofin was evaluated in six MCL cell lines (Z-138, JVM-2, Mino, Maver-1, Jeko-1, and Jeko-R) with auranofin in concentrations ranging from 0 to 5 μM for 72 h and tested cell viability using a luminescent assay. The confidence interval bars of observed dose-response in Fig. 5 show that the sample variance of error from repeated measurements decreased with the increase of auranofin concentrations. To account for the heteroscedasticity and asymmetry in the variance, we enable a dosedependent precision (proportional to inverse variance) in REAP, adding log( ) as an additional regressor for the precision parameter. Fig. 5 shows the fitted dose-response curves with the dosedependent precision. The test for homogeneity (p-value < 0.0001) suggests distinct dose-response between cell lines. The estimation of intercepts, hill coefficients and pairwise comparisons of IC50 estimations are provided in Supplementary Table 3 .

The second example is on the dose-response curve estimation in antiviral drug development for coronavirus disease 2019 . At the beginning of 2020, COVID-19 broke out at an unprecedented pace internationally, but there were limited therapeutic options for treating this disease. Therefore, many compounds and their combinations were rapidly tested in vitro against the SARS-CoV-2 virus to identify potentially effective treatments and prioritize clinical investigation.

In the data 25 , the benchmark compound collection consists of five known antivirals, including remdesivir, E64d (aloxistatin), chloroquine, calpain Inhibitor IV and hydroxychloroquine. The in vitro experiment was performed using the same biological batch of SARS-CoV-2 virus and conducted in biosafety level-3. In the original publication 25 , the dose-response curves were fitted by linear regression, which could yield inconclusive estimation (e.g., hydroxychloroquine in Fig. 1G of Bobrowski et al. (2020) 25 ), while the estimated inhibition tends to exceed 1 when concentration is larger than 10 M. REAP gives reasonable estimation for the dose-response curves (Fig. 6) . The hypothesis testing results show that at least one slope estimation is different from other antivirals (p-value = 0.0003) and at least one EC50 estimation is different from others (p-value = 0.003). Calpain Inhibitor IV shows a higher potency than other agents including hydroxychloroquine (p-value = 0.0038, Supplementary Table 4 ).

Quantifying the potency of a compelling substance is always a central topic in life sciences 26 . It is a vital component of research in pharmacology, but also prevalent in the fields of toxicology, environmental science, agrochemistry, and medicine, among many others. For instance, the description of dose-response curves can provide the initial toxicological risk assessment 27 , and guide in silico modeling of toxic doses to humans and the environment 28 . Based on proper identification of dose-response relationship from in vitro assays, studies can successfully predict systemic toxicological effects in vivo without additional in silico modelling 29 . Nevertheless, it necessitates accurate and reliable description of the dose-response curve, which further demands robust and efficient modeling strategies to account for embedded variability in observed response and to derive solid inference with valid quantification of uncertainty.

The dose-response estimation could be substantially biased by the standard regression modeling. In the illustrative example (Fig. 1) , the estimated IC50 dose indeed effects the 70% fraction of cell affected, while the estimated response at the true IC50 dose is only 22%. Such a large discrepancy is sourced by a small (<0.5%) single measurement error, which is common and inevitable in any regular in vivo experiment, but We develop REAP for assessment of drug potency to address concerns in this regard. It has substantial advantages over existing methods by reducing the impact of random errors due to implicit variations in the experimental data. The underlying robust beta regression model is resilient to estimation bias caused by extreme observations, which is a routinely encountered situation for deficient dose-response estimation using the standard estimation approach. The proposed approach is also efficient in quantitative characterization of dose-response curves with narrower confidence intervals for key estimators. Furthermore, REAP can simultaneously model the data heterogeneity with a dose-dependent precision component (Fig. 5) There is a venerable history that multi-agent combination therapies demonstrate great advantages in improving therapeutic efficacy and revolutionize patient outcomes in a wide range of diseases. Robust and efficient estimation of the dose-response curve would be crucial in investigation of adequate drug combinations.

The developed method has limitations. We presented a model of the median effect equation for doseresponse curve estimation based on mass action law. While in specific scenarios other laws may be considered more suitable to describe the biomedical systems, the current modeling framework can be naturally adapted for other dose-response functions like probit (via cumulative normal distribution) and

Weibull model 32 , or any other continuous distribution functions. In addition, the median-effect equation to characterize pharmacological activity assumes the compound can affect all the cells. From a quantitative perspective, a compound that cannot reach high binding affinity will yield an overconservative estimation for median effective dose of a drug. However, in comparison to the sensitivity of different compounds in an assay, it is not harmful because the less effective compounds will be more easily identified. If it is a concern that the maximal effects of candidate compounds are different and the aim is to accurately model the dose-response curve, the Emax model could be a better choice 33 .

Furthermore, the robust beta regression approach in REAP cannot handle values equal or less than 0, or equal or greater than 1. Thus, we developed a sequential data truncation algorithm in REAP to overcome the limitation of the conventional transformation (y * (n−1) + 0.5) / n, which could be too rough in doseresponse curve estimation particularly when the sample size n for each group is relatively small. Although empirically we have validated it using simulated data, the algorithm could be improved by future work to retain information more efficiently.

In summary, a good modeling strategy must effectively characterize the nature of the observed doseresponse pattern 16 . Rapid advances in novel drug development and considerable deficiency in modeling data with extreme values offer an appealing opportunity for next-generation quantitative approaches.

While many aspects of the techniques discussed here fit in the statistical framework of robust beta regression, our aim is to clearly apply and rigorously customize the analytic considerations, to reduce bias and ameliorate efficiency in routinely used dose-effect estimation, and to facilitate the convenient analytic implementation and dissemination. Experimental conditions and candidate drug potency could inevitably vary in practice, but REAP provides a great tolerance for points with extreme values, solid support for accurate and efficient dose-response curve estimation, and useful reference to the future development of methodology in drug investigation. Overall, we anticipate that our work will contribute more to quantitative analysis in assessment of drug potency in pre-clinical research. 

The authors report no potential conflicts of interest.

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

The median-effect principle and the combination index for quantitation of synergism and antagonism

The search for synergy: a critical review from a response surface perspective

Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction

An introduction to terminology and methodology of chemical synergy-perspectives from across disciplines

Computational tools for fitting the Hill equation to dose-response curves

Action limit outlier test: A novel approach for the identification of outliers in bioassay dose-response curves

Heteroskedasticity in the Linear Model

Statistical monitoring of heteroscedastic dose -Response profiles from high-throughput screening

Beta regression for modelling rates and proportions

Robust inference under the beta regression model with application to health care studies

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance

Nonlinear model-based estimates of IC50 for studies involving continuous therapeutic dose-response data

Continuous univariate distributions

Improved estimators for a general class of beta regression models

A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables

Regression analysis of variates observed on (0, 1): Percentages, proportions and fractions

Robust estimation in beta regression via maximum Lq-likelihood

A novel method for determining the inhibitory potential of anti-HIV drugs

Mathematical statistics: basic ideas and selected topics, volumes I-II package

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2

Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures. Theor

Toxicity testing in the 21st century: A vision and a strategy

The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans

Dose metric considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations

Numerically modelling time and dose dependent cytotoxicity

Interaction index and different methods for determining drug interaction in combination therapy

Dose-response functions in aquatic toxicity testing and the Weibull model